Australian peanut therapy developer Aravax reveals positive Phase I trial results at world-leading a

Melbourne biotech to take its revolutionary peanut allergy treatment to Phase II clinical trials

February 25, 2019, Melbourne, Australia – Aravax, a clinical stage biotechnology company focused on developing the next generation of peanut allergy immunotherapy with advantages in safety and practicality, has presented its clinical trial results at one of the world’s most prominent allergy conferences today.

Melbourne-based Aravax today announced positive results from the Phase I trial of its peanut allergy therapy, at the 2019 American Academy of Allergy, Asthma and Immunology (AAAAI) Annual Meeting in San Francisco. The trial data showed that Aravax’s therapy has a highly favorable safety profile, even in patients with severe peanut allergies.

Read more

Archive

Aravax


Tel: +61 (0)3 9657 0700
Email: info@aravax.com.au​
Address: Level 9, 31 Queen St

Melbourne, Victoria, 3000

Australia

Contact Us